Last reviewed 2026-06-02 · How we verify

Late HAART

Late HAART is a Antiretroviral combination therapy Small molecule drug developed by Hospital Nossa Senhora da Conceicao. It is currently FDA-approved for HIV-1 infection (initiated at advanced or late-stage disease).

Late HAART is a combination antiretroviral therapy regimen that suppresses HIV replication by inhibiting multiple stages of the viral life cycle.

Late HAART is a treatment approach for HIV infections that involves starting antiretroviral therapy when the disease is more advanced, often characterized by low CD4 cell counts. Late HAART typically involves the use of small molecule antiretroviral drugs such as nevirapine, zidovudine, and lamivudine.

At a glance

Mechanism of action

HAART (Highly Active Antiretroviral Therapy) typically combines drugs from different classes—such as nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), or integrase inhibitors—to achieve potent and durable HIV suppression. The term 'Late HAART' suggests initiation of therapy at a later stage of HIV infection, though the mechanism remains suppression of viral replication across multiple enzymatic targets.

Approved indications

• HIV-1 infection (initiated at advanced or late-stage disease)

Common side effects

• Nausea
• Diarrhea
• Headache
• Lipodystrophy
• Hepatotoxicity
• Immune reconstitution inflammatory syndrome (IRIS)

Key clinical trials

• Evaluating Strategies to Reduce Mother-to-Child Transmission of HIV Infection in Resource-Limited Countries (PHASE3)
• Perinatal Antiretroviral Intensification for PMTCT of HIV in Late Comers (PHASE3)
• Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV (NA)
• Early Antiviral Therapy for Critically Ill HIV Infected Patients (PHASE4)
• Effectiveness of Efavirenz-based Regimen in HIV-1-infected Patients With Nevirapine Hypersensitivity

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Late HAART CI brief — competitive landscape report
• Late HAART updates RSS · CI watch RSS
• Hospital Nossa Senhora da Conceicao portfolio CI

Frequently asked questions about Late HAART

Related

• Drug class: All Antiretroviral combination therapy drugs
• Manufacturer: Hospital Nossa Senhora da Conceicao — full pipeline
• Therapeutic area: All drugs in Infectious Disease / Virology
• Indication: Drugs for HIV-1 infection (initiated at advanced or late-stage disease)

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing